Non-Invasive Profiling of Advanced Prostate Cancer Via Multi-Parametric Liquid Biopsy and Radiomic Analysis
Overview
Chemistry
Molecular Biology
Authors
Affiliations
Integrating liquid biopsies of circulating tumor cells (CTCs) and cell-free DNA (cfDNA) with other minimally invasive measures may yield more comprehensive disease profiles. We evaluated the feasibility of concurrent cellular and molecular analysis of CTCs and cfDNA combined with radiomic analysis of CT scans from patients with metastatic castration-resistant PC (mCRPC). CTCs from 22 patients were enumerated, stained for PC-relevant markers, and clustered based on morphometric and immunofluorescent features using machine learning. DNA from single CTCs, matched cfDNA, and buffy coats was sequenced using a targeted amplicon cancer hotspot panel. Radiomic analysis was performed on bone metastases identified on CT scans from the same patients. CTCs were detected in 77% of patients and clustered reproducibly. cfDNA sequencing had high sensitivity (98.8%) for germline variants compared to WBC. Shared and unique somatic variants in PC-related genes were detected in cfDNA in 45% of patients (MAF > 0.1%) and in CTCs in 92% of patients (MAF > 10%). Radiomic analysis identified a signature that strongly correlated with CTC count and plasma cfDNA level. Integration of cellular, molecular, and radiomic data in a multi-parametric approach is feasible, yielding complementary profiles that may enable more comprehensive non-invasive disease modeling and prediction.
Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski J JAMA Netw Open. 2024; 7(10):e2437871.
PMID: 39374015 PMC: 11581504. DOI: 10.1001/jamanetworkopen.2024.37871.
Radiogenomics: bridging the gap between imaging and genomics for precision oncology.
He W, Huang W, Zhang L, Wu X, Zhang S, Zhang B MedComm (2020). 2024; 5(9):e722.
PMID: 39252824 PMC: 11381657. DOI: 10.1002/mco2.722.
Biomarkers for Prostate Cancer Bone Metastasis Detection and Prediction.
Ying M, Mao J, Sheng L, Wu H, Bai G, Zhong Z J Pers Med. 2023; 13(5).
PMID: 37240875 PMC: 10219132. DOI: 10.3390/jpm13050705.
Jiang L, Guo S, Zhao Y, Cheng Z, Zhong X, Zhou P Diagnostics (Basel). 2023; 13(10).
PMID: 37238217 PMC: 10217699. DOI: 10.3390/diagnostics13101734.
Yeo D, Kao S, Gupta R, Wahlroos S, Bastian A, Strauss H Front Oncol. 2023; 13:1141228.
PMID: 37051527 PMC: 10083432. DOI: 10.3389/fonc.2023.1141228.